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NEW VARIANT
Chlamydia trachomatis variant not detected by plasmid based
nucleic acid amplification tests: molecular characterisation
and failure of single dose azithromycin
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Objective: To characterise a Chlamydia trachomatis variant strain from a patient with non-gonococcal
urethritis (NGU) whose first void urine (FVU) displayed discrepant C trachomatis test results and describe the
clinical response to treatment.
Methods: The FVU specimen was assayed with an immune based Chlamydia Rapid Test (CRT) and various
nucleic acid amplification tests (NAATs) to establish C trachomatis infection. Sequencing of the major outer
membrane protein gene (omp1 also known as ompA) was undertaken to identify the serovar of the variant
strain. Polymerase chain reaction (PCR) analysis was also conducted to determine whether the strain
harboured deletions in the cryptic plasmid or was plasmid free.
Results: The FVU specimen was strongly reactive in CRT but negative with the plasmid based Amplicor PCR
(Roche) and ProbeTec ET (Becton-Dickinson) assays. However, NAATs for 16S RNA (Aptima Combo 2,
GenProbe), omp1 (RealArt CT PCR, Artus and in-house NAATs) or the outer membrane complex B protein
gene (omcB) established C trachomatis infection. Sequencing of omp1 showed that the variant belonged to
serovar I. PCR analysis indicated that the variant was plasmid free. The patient did not respond to single dose
azithromycin treatment but subsequently responded to a course of doxycycline.
Conclusions: A pathogenic plasmid free C trachomatis variant was identified. Clinicians should be alerted to
the possibility of undetected C trachomatis infection caused by such variants and the potential of azithromycin
failure in patients with recurrent chlamydial NGU. The occurrence of this variant is rare and should not form
the basis for judgment of the performance or usefulness of plasmid based NAATs for C trachomatis detection.
T
he organism Chlamydia trachomatis is the cause of the most
commonly reported bacterial sexually transmitted infec-
tions (STI) in developed countries such as the United States
and United Kingdom. The prevalence of C trachomatis infection
in these countries ranges from 3% to 20% among sexually active
young adults between 16 and 24 years of age.1 2 Untreated C
trachomatis infections can lead to complications such as pelvic
inflammatory disease and infertility in women and epididymi-
tis in men.3 Up to 80% of infected women and 50% of infected
men are asymptomatic,4 with most of these individuals
remaining undiagnosed. Targeted screening of high risk
populations has been recommended to control C trachomatis
infections,1 and several countries including the United
Kingdom have embarked on screening programmes based on
nucleic acid amplification tests (NAATs).2
Most commercial NAATs for the detection of C trachomatis
rely either on conserved regions of 16S ribosomal RNA or on the
7.5 kb cryptic plasmid of the organism as the target for
amplification.5 6 A C trachomatis variant with a deletion in the
plasmid was recently identified in Sweden, after an apparent
25% decrease in C trachomatis infections was noted.7 This variant
has a 377 bp deletion in the region of the plasmid targeted by
two NAATs, the M2000 (Abbott Laboratories, Abbott Park, IL,
USA) and Amplicor CT/NG PCR (Roche Diagnostic Systems,
Branchburg, NJ, USA) tests, and it therefore yielded false
negative results with both of these tests. However, this strain
remains detectable by another plasmid based NAAT, ProbeTec
ET (BD Biosciences, Sparks, MD, USA), because the deletion
does not affect the target region of this test. We now describe
the clinical presentation and characterisation of a C trachomatis
variant identified in the United Kingdom that generated false
negative results with all plasmid based NAATs but remained
detectable with assays based on 16S ribosomal RNA or outer
membrane protein genes.
METHODS
Patient and specimen collection
A 28-year-old heterosexual African man attended the Ambrose
King Centre (AKC) at the Royal London Hospital in December
2006 complaining of dysuria over a 3-week period. He was one
of the 904 male patients recruited for a study at the AKC
between March and December 2006 to evaluate the Chlamydia
Rapid Test (CRT) being developed by the Diagnostics
Development Unit at the University of Cambridge. This study
was approved by the Moorfields and Whittington research
ethics committee. Written informed consent was obtained from
the patient, and clinical research guidelines for the relevant
institutions were followed in the conduct of this research.
For the study, the patient was requested to provide 30–40 ml
of first void urine (FVU) after not having urinated for at least
2 hours. Before urine collection, the patient had a routine
urethral smear collected for Gram staining and culture for
Neisseria gonorrhoeae. Blood tests for treponemal and HIV
antibodies were performed. An aliquot of the FVU specimen
was tested for Mycoplasma genitalium using a real time
Abbreviations: CRT, Chlamydia Rapid Test; DPBS, Dulbecco’s phosphate
buffered saline; FVU, first void urine; hpf, high power field; GNID, Gram
negative intracellular diplococci; NAATs, nucleic acid amplification tests;
NGU, non-gonococcal urethritis; omp, outer membrane protein; PCR,
polymerase chain reaction; PMNL, polymorphonuclear leucocytes; STI,
sexually transmitted infections
339
www.stijournal.com
polymerase chain reaction (PCR) assay8 at the Sexually
Transmitted Bacteria Reference Laboratory of the Health
Protection Agency (HPA).
Chlamydia rapid test
The CRT was performed with 3 ml of the FVU specimen. The
urine was diluted with 6 ml water (Sigma, St Louis, MO, USA)
and then centrifuged at 3000 g for 20 minutes at room
temperature (Megafuge 1.0R; Hereaus, Osterode, Germany).
The resulting pellet was extracted with 400 ml of lysis agent,
300 ml of analyte stabiliser, and 100 ml of signal enhancer
reagent, with thorough mixing after the sequential addition of
each reagent. A portion (100 ml) of the resulting extract was
tested with a dipstick as previously described.9
Commercial NAATs
The following commercial NAATs were used to detect the
presence of C trachomatis in the FVU of the patient infected with
the newly identified variant: Amplicor CT/NG PCR, ProbeTec
ET, RealArt CT PCR (Artus, Hamburg, Germany), and Aptima
Combo 2 (GenProbe, San Diego, CA, USA). These tests were
performed according to manufacturers’ instructions.
In-house NAATs
The FVU specimen of the proband was also assayed by Taqman
based quantitative PCR (QPCR) tests that target the cryptic
plasmid or outer membrane complex B protein gene (omcB) of C
trachomatis . For these tests, 0.5 ml of urine was mixed with
0.5 ml of Dulbecco’s phosphate buffered saline (DPBS) without
Ca2+ and Mg2+ (BioWhittaker, Walkersville, MD, USA). The
mixture was centrifuged for 15 minutes at 17 000 g and 25 C˚
(Megafuge 1.0R). The resulting pellet was washed once with
DPBS and then resuspended in 100 ml of 2 M NH4OH (Sigma).
The tube was sealed, incubated at room temperature for 10
minutes, and then uncapped and incubated at 95˚(SD 1 C˚) for
60–70 minutes. The precipitate was resuspended in 0.5 ml of
nuclease free water (Sigma), and incubated for >30 minutes at
room temperature before amplification. QPCR was performed
by the method of Pickett et al10 using amplification conditions
described previously.11 Another real time PCR assay for the C
trachomatis plasmid was performed with the FVU specimen of
the proband as previously described.12
Extraction of DNA for PCR analysis of the cryptic
plasmid and omp1
A portion (0.5 ml) of the FVU specimen was centrifuged for
15 minutes at 17 000 g and 25 C˚ (Megafuge 1.0R), and the
resulting pellet was subjected to extraction with the use of a
QIAprep Miniprep Kit (Qiagen, Valencia, CA, USA). The same
method was also used for extraction of DNA from the culture
supernatant of the C trachomatis serovar I strain UW-12/Ur
(American Type Culture Collection), which served as control for
PCR assays.
PCR and sequence analysis of omp1
The entire major outer membrane protein gene (omp1 or ompA),
including the four variable sequence regions (VS1 to VS4), was
amplified by PCR with the forward primer MOMP-108 (corre-
sponding to position 108 bp upstream of omp1) and the reverse
primer RVSEND (corresponding to a position 80 bp downstream
of omp1). This primer set yields a 1327 bp fragment including
omp1. The primers MOMP87 (corresponding to a site located 87
bp downstream of omp1) and either RVS1163 or RVS1059
(corresponding to nucleotide positions 1163 and 1059 of the
gene, respectively) were used to amplify fragments of omp1. PCR
was performed with a GeneAmp 9700 thermal cycler (Applied
Biosystems, Foster City, CA, USA) and an Expand High Fidelity
kit (Roche). The 50 ml reaction mixture consisted of 5 ml of DNA
template, 15 pmol of each primer, 1.5 mM MgCl2, 200 mM of
each deoxynucleoside triphosphate, and 1.5 ml of Expand
polymerase in 1X reaction buffer. The amplification protocol
comprised an initial denaturation step at 95˚ C for 3 minutes; 40
cycles of denaturation (94 C˚, 40 seconds), annealing (50 C˚,
35 seconds), and extension (68˚ C, 2 minutes); and a final
extension step at 68˚ C for 10 minutes. The amplification
products were separated by electrophoresis on a 1.0% agarose
gel, purified with the use of a QIAquick gel extraction kit
(Qiagen), and sequenced with an Applied Biosystems 3730xl
DNA Analyzer at the Department of Biochemistry, University of
Cambridge. The primers used for omp1 amplification and
sequence analysis are shown in table 1. The determined
nucleotide sequence was aligned with published omp1 sequences
from various serovars with the use of MacVector V7.2.3 software
(Accelerys, Wigan). Another in-house PCR method13 was also
used to determine the presence of omp1 in the FVU specimen.
Table 1 Polymerase chain reaction and sequencing primers for omp1 and the cryptic plasmid
of C trachomatis
Primer Sequence (59 to 39) Nucleotide positions* and direction
PCR and sequencing primers for omp1
MOMP-10814 GGCCATTAATTGCTACAGGACATCTTGTC 780140–780168, forward
MOMP8714 TGAACCAAGCCTTATGATCGACGG 779951–779974, forward
RVSEND15 AAGYCGAGCCCAGAAAYACGGAT 778798–778020, reverse
RVS116314 CGGAATTGTGCATTTACGTGAG 778886–778907, reverse
RVS105914 GCAATACCGCAAGATTTTCTAGATTTCATC 778982–779011, reverse
CT419F16 TGGGATCGTTTTGATGTATT 779654–779673, forward
CT902F16 TACATTGGAGTTAAATGGTC 779183–779202, forward
PCR primers for the cryptic plasmid
Seq30F TGGTACGAGAAGGTGATTCTAAGCC 5244–5268, forward
LCR20R17 CAACAAAAGTCCATTATGACC 91–111, reverse
Seq31F AGTCTTCTGCTTACAATGCTCTTGC 7046–7070, forward
Seq4F CCAAGCTTAAGACTTCAGAGGAGCG 1538–1562, forward
Seq6R GCCAGCACTCCAATTTCTGACTGTG 2742–2766, reverse
Seq21F TCCCTCGTGATATAACCTATCCG 2131–2153, forward
Seq7F GTTGGGAAAAATAGACATGGATCGG 3488–3152, forward
CtpFPR18 TGGGTGTGACTGTGAATTTTCC 5147–5168, reverse
Seq10F GTGTCTCACTAATTCTAGGACTGCT 5709–5733, forward
Seq8F CGTTGTAGAGCCATGTCCTATCTTG 4164–4188, forward
LCR25R17 AGAATTCAAAGTTGCTGAGAATA 6785–6807, reverse
*Nucleotide positions correspond to the regions of the genome (for omp1) or of the plasmid pLGV440 (GenBank
accession number X06707) targeted by each primer.
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PCR analysis of the cryptic plasmid
Various regions of the C trachomatis cryptic plasmid were
amplified by PCR with combinations of primers that together
encompass the entire plasmid (table 1). PCR was performed as
described above for omp1, with the exception that annealing
was performed at 54 C˚ and extension time for the 40 cycles was
increased to 3 minutes. Seven primer pairs were used for
analysis of the plasmid: (1) Seq30F and LCR20R, (2) Seq31F
and Seq6R, (3) Seq4F and Seq6R, (4) Seq21F and CtpFPR, (5)
Seq7F and CtpFPR, (6) Seq10F and LCR25R, and (7) Seq8F and
LCR25R. PCR products were separated by electrophoresis on a
1% agarose gel and were visualised by staining with ethidium
bromide.
RESULTS
The patient complained of pain during urination and revealed
that he had engaged in unprotected vaginal sexual intercourse
with four partners in the United Kingdom and mainland
Europe during the preceding 3 months. Genital examination
revealed a clear urethral discharge, microscopic examination of
which showed 30 polymorphonuclear leucocytes per high
power field (PMNL/hpf) 61000 but no Gram negative
intracellular diplococci (GNID), indicating non-gonococcal
urethritis (NGU). Culture for Neisseria gonorrhoeae, treponemal
enzyme immunoassay test, HIV antibody test, and an in-house
real time PCR assay for Mycoplasma genitalium were all negative.
The FVU specimen was also negative for C trachomatis by the
ProbeTec ET assay, the routine NAAT used to detect C
trachomatis at the hospital.
The FVU was tested with both the CRT and the Amplicor CT/
NG PCR assay; it was found to be strongly reactive in the
former but negative in the latter. To examine whether the CRT
result was a false positive, we performed two TaqMan PCR
assays10 to detect omcB or the cryptic plasmid. The sample was
clearly positive for omcB (mean 47 770 (SD 7103) copies per
millilitre of urine; n = 3) but negative for the plasmid. The FVU
was also negative with another in-house plasmid based PCR
assay12 but yielded positive results when tested in two different
laboratories by alternative NAATs that target omp1 (RealArt CT
PCR and an in-house PCR assay13). The Aptima Combo 2 assay,
which targets 16S ribosomal RNA, also established the presence
of C trachomatis infection in the patient. Sequencing analysis
revealed that omp1 of the C trachomatis strain detected in the
proband is identical to that of the serovar Ia strain Ia/CL-9 (CS-
190/96).19 The results of the various C trachomatis tests
performed on the patient’s urine are summarised in table 2.
The patient was treated for NGU with azithromycin (1 g
immediately). Six weeks later, he reported initial symptomatic
improvement, with a recurrence of dysuria and urethral
discharge during the previous week. Examination revealed a
mucoid urethral discharge, microscopic analysis of which
revealed 50 PMNL/hpf (61000) but no GNID. He was again
treated for NGU but with 100 mg of doxycycline twice daily for
1 week. Repeat testing on a FVU sample with the use of
plasmid based NAATs (ProbeTec ET, Amplicor CT/NG PCR, and
TaqMan PCR) was negative, whereas the Taqman PCR test for
omcB remained positive, although the C trachomatis load (3496
(SD 671) copies/ml) was much lower than that of the initial
specimen. Real time PCR for M genitalium remained negative.
The NAAT results indicate that the C trachomatis strain detected
during the second clinic visit was the same strain observed
earlier.
To investigate further why the variant C trachomatis strain
was not detected with plasmid based NAATs, PCR was
performed with primers designed to yield overlapping products
covering the entire 7.5 kb cryptic plasmid (table 1). DNA
extracted from a culture supernatant of the serovar I strain
UW-12/Ur was used as a positive control. Whereas the seven
primer combinations yielded amplification products of the
expected sizes with the control strain, no amplification
products were detected with DNA isolated from the variant
strain (fig 1A). The plasmid map indicating the regions covered
by the plasmid amplification products is shown in figure 1B.
Twenty-six additional primer combinations that target different
regions of the plasmid also yielded amplification products with
DNA from the serovar I strain but not with the variant strain
(data not shown). The DNA extracts used for amplification of
the plasmid for both the serovar I and the variant strains,
however, yielded products of the expected size when used to
amplify omp1 (fig 1A). These results suggest that this C
trachomatis variant is a plasmid free strain.
DISCUSSION
NAATs are considered the most sensitive tests for the diagnosis
of C trachomatis infection.5 6 The targets for nucleic acid
amplification in these tests include the cryptic plasmid, major
outer membrane protein complex genes (omp1, omcB), and 16S
ribosomal RNA.20 The plasmid is a preferred target for many
NAATs because its presence in multiple copies renders plasmid
based tests more sensitive than chromosome based ones.21
Indeed, three of four major commercial platforms for C
trachomatis detection used in North America and Europe are
plasmid based NAATs. Although the plasmid is well conserved
among C trachomatis strains,22 plasmid free variants have been
described.23 24 The use of plasmid based NAATs for systematic
screening over a long period may result in diagnostic selection
pressure and the consequent emergence of plasmid free
strains20 and false negative test results.
The present case reveals a novel C trachomatis variant that was
not detected with any of the plasmid based NAATs applied and
is therefore a plasmid free strain which differs from the variant
strain reported in Sweden.7 Investigations conducted in
Table 2 C trachomatis tests performed on the urine sample of the proband
Test manufacturer or developer Test name Test target Result
Commercial tests
BD Biosciences ProbeTec ET Plasmid –
Roche Amplicor CT/NG PCR Plasmid –
Artus RealArt CT PCR omp1 +
GenProbe Aptima Combo 2 16S ribosomal RNA +
University of Cambridge Chlamydia Rapid Test Lipopolysaccharide +
Research tests
CDC and HPA Real time PCR12 Plasmid –
University of Southampton Taqman PCR10 Plasmid –
University of Southampton Taqman PCR10 omcB +
LSHTM omp1 PCR13 omp1 +
CDC, Centers for Disease Control and Prevention; HPA, Health Protection Agency; LSHTM, London School of Hygiene
and Tropical Medicine.
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Ireland,25 the United Kingdom,26 and the Netherlands27 did not
identify the latter strain in these countries. However, recent
studies have reported detection of the Swedish variant in
patients attending STI clinics in Norway28 and Denmark.29
It was not possible to establish a definite source of the
patient’s infection, given that he had partners both in the
United Kingdom and mainland Europe before his first clinic
visit. We succeeded in tracing two of his four partners, and both
were negative for C trachomatis in tests performed elsewhere,
although one of them was previously diagnosed and treated for
non-gonococcal ‘‘cervicitis’’. Follow-up C trachomatis tests on
cervical swab and FVU specimens from these two partners were
negative for both the plasmid and omcB using Taqman PCR.
The persistent urethritis in our patient may have been due
either to a poor response to azithromycin treatment or to re-
infection from a new partner; the latter possibility is highly
unlikely given that he disclosed only protected intercourse
between his two clinic visits. More importantly, the NAAT
results on the second FVU specimen indicate that the C
trachomatis strain detected was identical to that observed during
his first clinic visit and thus support the possibility of the failure
of azithromycin treatment. Azithromycin failure in the absence
of re-infection has been reported in women30 and with
multidrug resistant strains.31 In the present patient, an initial
response to azithromycin was followed by symptom relapse and
clinical and laboratory evidence of urethritis, albeit with a lower
chlamydial load. These observations are suggestive of reactiva-
tion of persistent infection resulting from heterotypic resistance
associated with a high chlamydial load.32
The patient’s high risk activities, the inability of plasmid
based NAATs to detect the C trachomatis strain responsible for
his infection, the failure of single dose azithromycin treatment,
and the fact that a large proportion of C trachomatis infections
are asymptomatic suggest that other cases of infection with this
variant strain may have gone undetected in settings that rely
solely on plasmid based NAATs for C trachomatis detection.
However, retrospective testing using CRT and Amplicor PCR of
almost 300 C trachomatis positive urine samples (112 female,
183 male) obtained from screening 3739 individuals attending
STI and young people’s sexual health clinics in 2006 failed to
detect the presence of variant strains, indicating that it is not
highly prevalent. A prospective study to determine the
frequency of plasmid variants will be initiated by the HPA.
Until additional data become available, this report remains an
isolated case and should not form the basis for judgment either
of the performance of the various NAAT assay systems or of the
efficacy of treatment regimens. Nevertheless, it is important to
recognise the possible existence of undetected C trachomatis
infections caused by variant strains in STI clinics or C
trachomatis screening programmes, especially in settings where
plasmid based NAATs are the method of choice for diagnosis of
such infection.
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